---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-038925"
form_type: "8-K"
ticker: null
cik: "0000786947"
company_name: "ACURA PHARMACEUTICALS, INC"
filed_at: "2024-03-26T23:59:59+00:00"
generated_at: "2026-06-04T08:14:22.307564+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Acura extends NDA acceptance date for LTX-03 and note maturity to June 30, 2024

## Summary
- Amendment #8 to License Agreement extends FDA NDA acceptance deadline for LTX-03 from March 31 to June 30, 2024.
- If NDA not accepted by June 30, AD Pharma may terminate and take ownership of LTX-03 IP.
- Amendment #2 to Promissory Note extends maturity to June 30, 2024; principal $5.4M at 5.25% interest.
- AD Pharma, which owns ~65% of Acura common stock, may terminate license agreement at any time.

## SEC filing metadata
- accession: 0001104659-24-038925
- form_type: 8-K
- cik: 0000786947
- company_name: ACURA PHARMACEUTICALS, INC
- filed_at: 2024-03-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/786947/000110465924038925/0001104659-24-038925-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/786947/000110465924038925/tm249762d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-038925
- JSON: https://secwatch.observer/filing/0001104659-24-038925.json
- Plain text: https://secwatch.observer/filing/0001104659-24-038925.txt

## Key facts
- Debt Financings
  ACURA PHARMACEUTICALS, INC amended debt with Abuse Deterrent Pharma, LLC at 5.25% maturing June 30, 2024.
  - Counterparty: Abuse Deterrent Pharma, LLC
  - Rate: 5.25%
  - Maturity: June 30, 2024
  - Event: amendment
  source text: Amendment #2 has an effective date of March 15, 2024 and changes the maturity date of the Note from March 31, 2024 to June 30, 2024, at which time all principal and interest is due.
  evidence_url: https://www.sec.gov/Archives/edgar/data/786947/000110465924038925/0001104659-24-038925-index.htm
- Material Agreements
  ACURA PHARMACEUTICALS, INC amended Amended Agreement with Abuse Deterrent Pharma, LLC (effective 2024-03-25).
  - Action: amendment
  - Agreement: collaboration
  - Counterparty: Abuse Deterrent Pharma, LLC
  - Effective: 2024-03-25
  source text: On March 25, 2024, Acura Pharmaceuticals, Inc. (“we” “Acura” or the “Company”), received the executed agreement to further amend the June 28, 2019 License, Development and Commercialization Agreement (“Agreement”) with Abuse Deterrent Pharma, LLC (“AD Pharma”), for the development of LTX-03 (hydrocodone bitartrate with acetaminophen) immediate-release tablets utilizing Acura’s patented LIMITx technology which addresses the consequences of excess oral administration of opioid tablets, the most prevalent route of opioid overdose and abuse. The amendment to the Agreement extends the FDA’s acceptance date of a New Drug Application (“NDA”) for LTX-03 to June 30, 2024 (“NDA Acceptance Date”) (“Amended Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/786947/000110465924038925/0001104659-24-038925-index.htm
- Material Agreements
  ACURA PHARMACEUTICALS, INC amended Amendment #2 with Abuse Deterrent Pharma, LLC (effective 2024-03-15).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: Abuse Deterrent Pharma, LLC
  - Effective: 2024-03-15
  source text: On March 25, 2024, Acura Pharmaceuticals, Inc. (“we” “Acura” or the “Company”), received the executed agreement to further amend the November 10, 2022 Amended, Consolidated and Restated Secured Promissory Note (the “Note”) with Abuse Deterrent Pharma, LLC (“AD Pharma”). Amendment #2 has an effective date of March 15, 2024 and changes the maturity date of the Note from March 31, 2024 to June 30, 2024, at which time all principal and interest is due. As of March 15, 2024, the Note’s principal balance was $5,419,279, bears interest at 5.25%, and had an accrued interest balance of approximately $265,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/786947/000110465924038925/0001104659-24-038925-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.